Inhibition of human platelet function by verapamil

Area of Science:

• Pharmacology
• Hematology
• Cardiovascular Research

Background:

• Platelet activation is crucial in hemostasis and thrombosis.
• Epinephrine and calcium play key roles in platelet aggregation.
• Verapamil is a calcium channel blocker with potential effects on platelet function.

Purpose of the Study:

• To investigate the effects of verapamil on human platelet function.
• To determine the specificity and reversibility of verapamil's anti-platelet activity.
• To elucidate the mechanisms underlying verapamil's interaction with platelet activation pathways.

Main Methods:

• In vitro evaluation of verapamil's impact on platelet aggregation and serotonin release.
• Dose-response studies using varying concentrations of verapamil, epinephrine, and calcium.
• Assessment of verapamil's effect on thromboxane B2 release and 14C-serotonin uptake.
• Reversibility testing through platelet gel-filtration.

Main Results:

• Verapamil inhibited epinephrine-induced platelet aggregation and 14C-serotonin release in a dose-dependent manner.
• Verapamil reduced 14C-serotonin uptake and prevented thromboxane B2 release.
• The inhibitory effects of verapamil were surmountable by increased epinephrine or calcium concentrations.
• Verapamil's anti-platelet activity was reversible and specific to epinephrine-induced activation, with minimal effect on ADP or calcium ionophore-induced aggregation.

Conclusions:

• Verapamil acts as a reversible, specific inhibitor of epinephrine-induced platelet activation at tested concentrations.
• The mechanism may involve competitive inhibition of epinephrine binding and blockade of calcium flux.
• Verapamil's anti-platelet effects are transient and dependent on its plasma concentration.